HRP20191305T1 - Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste - Google Patents
Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste Download PDFInfo
- Publication number
- HRP20191305T1 HRP20191305T1 HRP20191305TT HRP20191305T HRP20191305T1 HR P20191305 T1 HRP20191305 T1 HR P20191305T1 HR P20191305T T HRP20191305T T HR P20191305TT HR P20191305 T HRP20191305 T HR P20191305T HR P20191305 T1 HRP20191305 T1 HR P20191305T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide according
- polypeptide
- biologically active
- group
- active part
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 17
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 8
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 8
- 239000003114 blood coagulation factor Substances 0.000 claims 8
- 238000003776 cleavage reaction Methods 0.000 claims 4
- 230000007017 scission Effects 0.000 claims 4
- 230000002255 enzymatic effect Effects 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000000284 resting effect Effects 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Claims (16)
1. Polipeptid, koji sadrži
(i) barem jedan biološki aktivan dio koji sadrži faktor zgrušavanja,
(ii) Fc regiju koja sadrži najmanje dva Fc dijela, i
(iii) scFc (cscFc) poveznicu koja se može cijepati umetnutu između dva Fc dijela, pri čemu je cscFc poveznica okružena s mjestom enzimatskog cijepanja i uzvodno i nizvodno od cscFc poveznice, što rezultira cijepanjem cscFc poveznice.
2. Polipeptid prema patentnom zahtjevu 1, naznačen time što sadrži drugi biološki aktivan dio.
3. Polipeptid prema patentnom zahtjevu 2, naznačen time što je drugi biološki aktivan dio odabran iz skupine koja se sastoji od: antigen vezujućeg dijela protutijela, ne-imunoglobulinske vezujuće molekule, veznog dijela liganda, veznog dijela receptora, i faktora zgrušavanja.
4. Polipeptid prema patentnom zahtjevu 2 ili 3, naznačen time što polipeptid ima formulu izabranu iz skupine koja se sastoji od: A-F1-B-P1-L-P2-F2; A-F1-P1-L-P2-B-F2; A-F1-P1-L-P2-F2; i F1-P1-L-P2-B-F2; u linearnoj sekvenci od amino do karboksi terminalnog kraja, i
pri čemu A je barem jedan biološki aktivan dio;
B je drugi biološki aktivan dio;
P1 je prvo mjesto enzimatskog cijepanja;
P2 je drugo mjesto enzimatskog cijepanja;
L je cscFc poveznica; i
F1 i F2 su Fc dijelovi.
5. Polipeptid prema patentnom zahtjevu 4, naznačen time što najmanje jedan od P1 ili P2 sadrži aminokiselinsku sekvencu odabranu iz skupine koju čine: TQSFNDFTR, SVSQTSKLTR, DFLAEGGGVR, TTKIKPR, LVPRG, i ALRPR.
6. Polipeptid prema patentnom zahtjevu 4, naznačen time što najmanje jedan od P1 ili P2 sadrži aminokiselinsku sekvencu odabranu iz skupine koju čine: RRRR, RKRRKR, i RRRRS.
7. Polipeptid prema patentnom zahtjevu 2, naznačen time što:
(i) prvi biološki aktivan dio sadrži lagani lanac faktora zgrušavanja; i
(ii) drugi biološki aktivan dio sadrži teški lanac faktora zgrušavanja;
pri čemu Fc regija sadrži prvi Fc dio i drugi Fc dio;
pri čemu je prvi Fc dio vezan na lagani lanac faktora zgrušavanja i drugi Fc dio je vezan na teški lanac faktora zgrušavanja; i
pri čemu se lagani lanac i teški lanac vežu tako da tvore enzimatski aktivni faktor zgrušavanja.
8. Polipeptid prema patentnom zahtjevu 3 ili 7, naznačen time što je faktor zgrušavanja odabran iz skupine koja se sastoji od FVII, FVIIa, FIX, FIXa, FX, i FXa.
9. Polipeptid prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time što nadalje sadrži ciljajući dio.
10. Polipeptid prema patentnom zahtjevu 9, naznačen time što se ciljajući dio selektivno veže na mirujuće trombocite ili selektivno veže na aktivirane trombocite.
11. Molekula nukleinske kiseline naznačena time što kodira polipeptid prema bilo kojem od patentnih zahtjeva 1 do 10.
12. Vektor naznačen time što sadrži molekulu nukleinske kiseline prema patentnom zahtjevu 11.
13. Stanica domaćin koja sadrži vektor prema patentnom zahtjevu 12, naznačena time što stanica domaćina eksprimira enzim koji cijepa cscFc poveznicu, pri čemu je enzim endogeni ili egzogeni za stanicu.
14. Postupak za proizvodnju obrađenog, heterodimernog polipeptida koji sadrži dva polipeptidna lanca, naznačen time što obuhvaća kultiviranje stanice domaćina prema zahtjevu 13 u mediju stanične kulture i izoliranje zrelog, heterodimernog polipeptida iz medija kulture.
15. Pripravak naznačen time što sadrži polipeptid prema bilo kojem od patentnih zahtjeva 1 do 10 i farmaceutski prihvatljiv nosač.
16. Pripravak prema patentnom zahtjevu 15, naznačen time što je za uporabu za liječenje ili prevenciju bolesti ili poremećaja kod subjekta.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36318310P | 2010-07-09 | 2010-07-09 | |
US36318610P | 2010-07-09 | 2010-07-09 | |
US201161442029P | 2011-02-11 | 2011-02-11 | |
US201161442150P | 2011-02-11 | 2011-02-11 | |
US201161442055P | 2011-02-11 | 2011-02-11 | |
US201161467880P | 2011-03-25 | 2011-03-25 | |
US201161491762P | 2011-05-31 | 2011-05-31 | |
EP11738539.3A EP2591006B1 (en) | 2010-07-09 | 2011-07-11 | Processable single chain molecules and polypeptides made using same |
PCT/US2011/043599 WO2012006635A1 (en) | 2010-07-09 | 2011-07-11 | Processable single chain molecules and polypeptides made using same |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20191305T1 true HRP20191305T1 (hr) | 2019-10-18 |
Family
ID=44629302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191305TT HRP20191305T1 (hr) | 2010-07-09 | 2019-07-18 | Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste |
Country Status (22)
Country | Link |
---|---|
US (6) | US20130216513A1 (hr) |
EP (3) | EP2591099B1 (hr) |
JP (1) | JP2013534427A (hr) |
KR (1) | KR20140002601A (hr) |
CN (1) | CN103180439A (hr) |
AU (1) | AU2011274423B2 (hr) |
CA (1) | CA2804280A1 (hr) |
CY (1) | CY1122044T1 (hr) |
DK (2) | DK2591099T3 (hr) |
EA (1) | EA201291482A1 (hr) |
ES (1) | ES2739503T3 (hr) |
HR (1) | HRP20191305T1 (hr) |
HU (1) | HUE044419T2 (hr) |
LT (1) | LT2591006T (hr) |
MX (1) | MX2013000301A (hr) |
NZ (1) | NZ605400A (hr) |
PL (1) | PL2591006T3 (hr) |
PT (1) | PT2591006T (hr) |
SG (2) | SG186875A1 (hr) |
SI (1) | SI2591006T1 (hr) |
TW (2) | TW201217527A (hr) |
WO (2) | WO2012006635A1 (hr) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US20110046060A1 (en) | 2009-08-24 | 2011-02-24 | Amunix Operating, Inc., | Coagulation factor IX compositions and methods of making and using same |
WO2010091122A1 (en) | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
TW201217527A (en) | 2010-07-09 | 2012-05-01 | Biogen Idec Hemophilia Inc | Processable single chain molecules and polypeptides made using same |
DK2635607T3 (da) | 2010-11-05 | 2019-11-18 | Zymeworks Inc | Stabilt heterodimert antistofdesign med mutationer i fc-domænet |
WO2012116453A1 (en) | 2011-03-03 | 2012-09-07 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
SI2717898T1 (sl) | 2011-06-10 | 2019-07-31 | Bioverativ Therapeutics Inc. | Spojine prokoagulantov in metode za njihovo uporabo |
TWI687226B (zh) * | 2011-07-08 | 2020-03-11 | 美商百歐維拉提夫治療公司 | 因子viii嵌合及雜交多肽,及其使用方法 |
HRP20211773T1 (hr) | 2011-11-04 | 2022-03-04 | Zymeworks Inc. | Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni |
WO2013096932A1 (en) * | 2011-12-23 | 2013-06-27 | Vasculogics, Inc. | Compositions and methods for treatment of thrombosis and prolonging survival of stored platelets |
KR101963230B1 (ko) * | 2011-12-26 | 2019-03-29 | 삼성전자주식회사 | 복수개의 단일 항체를 포함하는 단백질 복합체 |
CN111499760A (zh) | 2012-01-12 | 2020-08-07 | 比奥贝拉蒂治疗公司 | 嵌合因子viii多肽及其用途 |
CA2861124A1 (en) * | 2012-02-10 | 2013-08-15 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
PT2814840T (pt) | 2012-02-15 | 2020-01-28 | Bioverativ Therapeutics Inc | Composições de fator viii e métodos de produção e utilização das mesmas |
EP2822577B1 (en) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
RU2014148704A (ru) * | 2012-05-10 | 2016-07-10 | Займворкс Инк. | Конструкции одноруких моновалентных антител и их использование |
WO2013185113A1 (en) * | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Procoagulant compounds |
CN104427995A (zh) * | 2012-06-08 | 2015-03-18 | 比奥根艾迪克Ma公司 | 嵌合凝血因子 |
WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
CA2871880A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
MX2014014804A (es) | 2012-06-27 | 2015-02-12 | Hoffmann La Roche | Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo. |
RS59876B1 (sr) | 2012-07-11 | 2020-03-31 | Bioverativ Therapeutics Inc | Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena |
WO2014012082A2 (en) | 2012-07-13 | 2014-01-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design an constructs |
KR101974583B1 (ko) * | 2012-08-29 | 2019-05-02 | 삼성전자주식회사 | 링커 폴리펩티드 및 이를 이용한 표적 물질 분석 방법 |
WO2014063108A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
KR101911438B1 (ko) | 2012-10-31 | 2018-10-24 | 삼성전자주식회사 | 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법 |
US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
US10081678B2 (en) | 2013-02-04 | 2018-09-25 | Emory University | Specific binding antibodies of glycoprotein IB alpha as selective ectodomain shedding inhibitors |
US10370431B2 (en) | 2013-02-15 | 2019-08-06 | Bioverativ Therapeutics Inc. | Optimized factor VIII gene |
EP2964676A1 (en) * | 2013-03-06 | 2016-01-13 | Merrimack Pharmaceuticals, Inc. | Anti-c-met tandem fc bispecific antibodies |
SG10201707600XA (en) | 2013-03-15 | 2017-11-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
US10364288B2 (en) | 2013-05-24 | 2019-07-30 | Biogen Ma Inc. | Anti-GPIIB/IIIA antibodies or uses thereof |
CN104211799B (zh) * | 2013-05-29 | 2017-12-26 | 成都渊源生物科技有限公司 | 人源egf结构域蛋白及其应用 |
TW201536811A (zh) * | 2013-05-31 | 2015-10-01 | Biogen Idec Inc | 嵌合fvii-xten分子及其用途 |
NZ713904A (en) | 2013-06-28 | 2022-02-25 | Bioverativ Therapeutics Inc | Thrombin cleavable linker with xten and its uses thereof |
EP3043813B1 (en) * | 2013-08-08 | 2021-01-13 | Bioverativ Therapeutics Inc. | Purification of chimeric fviii molecules |
TW202003554A (zh) | 2013-08-14 | 2020-01-16 | 美商百歐維拉提夫治療公司 | 因子viii-xten融合物及其用途 |
US20160311885A1 (en) | 2013-08-14 | 2016-10-27 | Biogen Ma Inc. | Recombinant factor viii proteins |
CN103599527A (zh) * | 2013-08-16 | 2014-02-26 | 安源生物科技(上海)有限公司 | 包含改良型人凝血因子FVII-Fc融合蛋白的药物组合物 |
CN103397009B (zh) * | 2013-08-16 | 2015-06-03 | 安源生物科技(上海)有限公司 | 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途 |
MX2016003871A (es) * | 2013-09-24 | 2016-08-04 | Pfizer | Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion. |
ES2900425T3 (es) | 2013-09-25 | 2022-03-16 | Bioverativ Therapeutics Inc | Métodos de inactivación vírica en columna |
US10584147B2 (en) | 2013-11-08 | 2020-03-10 | Biovertiv Therapeutics Inc. | Procoagulant fusion compound |
AU2014357292B2 (en) | 2013-11-27 | 2020-06-25 | Zymeworks Bc Inc. | Bispecific antigen-binding constructs targeting HER2 |
EP3083933A1 (en) | 2013-12-20 | 2016-10-26 | Biogen MA Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
SI4176894T1 (sl) | 2014-01-10 | 2024-07-31 | Bioverativ Therapeutics Inc. | Himerni proteini faktorja VIII in njihova uporaba |
DK3137506T3 (da) | 2014-05-02 | 2023-10-02 | Momenta Pharmaceuticals Inc | Sammensætninger og fremgangsmåder relateret til genmanipulerede fc-konstrukter |
CA2946503C (en) | 2014-05-28 | 2022-11-22 | Zymeworks Inc. | Modified antigen binding polypeptide constructs and uses thereof |
CN105294857B (zh) * | 2014-06-18 | 2019-02-19 | 上海交通大学 | 基于fix的抗原表位及其应用 |
US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
WO2016033100A1 (en) | 2014-08-25 | 2016-03-03 | Salk Institute For Biological Studies | Novel ulk1 inhibitors and methods using same |
TWI700300B (zh) * | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體 |
ES2753391T3 (es) | 2014-10-14 | 2020-04-08 | Halozyme Inc | Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas |
MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
EP3227332B1 (en) | 2014-12-03 | 2019-11-06 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
WO2016118577A1 (en) * | 2015-01-22 | 2016-07-28 | Medimmune, Llc | Thymosin-beta-four fusion proteins |
JP7136690B2 (ja) * | 2015-06-12 | 2022-09-13 | ユービーアイ ファーマ インク | 免疫グロブリン融合タンパク質およびその使用 |
JP6909203B2 (ja) | 2015-08-03 | 2021-07-28 | バイオベラティブ セラピューティクス インコーポレイテッド | 第ix因子融合タンパク質及びそれらの製造方法及び使用方法 |
WO2017079768A1 (en) * | 2015-11-08 | 2017-05-11 | Genentech, Inc. | Methods of screening for multispecific antibodies |
CN108884145B (zh) | 2015-11-13 | 2023-08-22 | 武田药品工业株式会社 | 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体 |
MX2018009375A (es) | 2016-02-01 | 2018-09-05 | Bioverativ Therapeutics Inc | Genes del factor viii optimizados. |
SG11201810466PA (en) | 2016-05-23 | 2018-12-28 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
BR112019000071A2 (pt) | 2016-07-07 | 2019-07-02 | Bolt Biotherapeutics Inc | conjugados adjuvantes de anticorpo |
WO2018027124A1 (en) | 2016-08-05 | 2018-02-08 | Medimmune, Llc | Anti-o2 antibodies and uses thereof |
CN106279437B (zh) * | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
CN107759694B (zh) | 2016-08-19 | 2023-01-13 | 安源医药科技(上海)有限公司 | 双特异性抗体及其制备方法与用途 |
US20190248920A1 (en) * | 2016-09-23 | 2019-08-15 | Csl Limited | Coagulation factor binding proteins and uses thereof |
AU2017346488A1 (en) | 2016-10-19 | 2019-05-30 | Humabs Biomed Sa | Anti-O1 antibodies and uses thereof |
CN110072885B (zh) | 2016-11-17 | 2023-12-19 | 2赛文缇生物公司 | TGFβ信号转换器 |
CN110650748B (zh) | 2017-01-06 | 2024-01-02 | 动量制药公司 | 与经工程改造的Fc构建体相关的组合物和方法 |
US20190388522A1 (en) * | 2017-01-25 | 2019-12-26 | Iconic Therapeutics, Inc. | Methods for treating disorders associated with angiogenesis and neovascularization |
AR110871A1 (es) | 2017-01-31 | 2019-05-08 | Bioverativ Therapeutics Inc | Proteínas de fusión de factor ix y métodos de fabricación y uso de las mismas |
AU2018235945A1 (en) * | 2017-03-14 | 2019-10-17 | Ohio State Innovation Foundation | Methods and compositions related to a tissue factor-targeting IgG3 immunoconjugates |
KR20200035130A (ko) | 2017-08-09 | 2020-04-01 | 바이오버라티브 테라퓨틱스 인크. | 핵산 분자 및 이의 용도 |
AU2018341227A1 (en) * | 2017-09-27 | 2020-04-09 | Ohio State Innovation Foundation | Tissue factor-targeting CAR-NK and CAR-T cell therapy |
KR101952102B1 (ko) * | 2017-12-07 | 2019-02-26 | 주식회사 지앤피바이오사이언스 | 단백질 발현량이 증대된 인자 ⅷ 변이체 발현벡터 |
SG11202007114VA (en) | 2018-02-01 | 2020-08-28 | Bioverativ Therapeutics Inc | Use of lentiviral vectors expressing factor viii |
TW202003555A (zh) | 2018-03-07 | 2020-01-16 | 英商葛蘭素史克智慧財產發展有限公司 | 用於純化重組多肽之方法 |
EP3793588A1 (en) | 2018-05-18 | 2021-03-24 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia a |
US20210155710A1 (en) | 2018-06-05 | 2021-05-27 | Amgen Inc. | Modulating antibody dependent cellular phagocytosis |
WO2019241847A1 (en) * | 2018-06-22 | 2019-12-26 | Baker Heart and Diabetes Institute | A therapeutic gpiib/iiia binding-protein drug conjugate and use thereof |
SG11202101157VA (en) | 2018-08-09 | 2021-03-30 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof for non-viral gene therapy |
GB201813528D0 (en) * | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
CN110678484B (zh) * | 2018-08-21 | 2022-12-27 | 天境生物科技(杭州)有限公司 | 抗pd-l1/抗lag3双特异性抗体及其用途 |
WO2020055900A1 (en) | 2018-09-11 | 2020-03-19 | Amgen Inc. | Methods of modulating antibody-dependent cell-mediated cytotoxicity |
WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
CA3121786A1 (en) | 2018-12-06 | 2020-06-11 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor ix |
KR20210117291A (ko) | 2019-01-16 | 2021-09-28 | 박스알타 인코퍼레이티드 | A형 혈우병의 유전자 요법을 위한 증가된 발현을 갖는 재조합 fviii 변이체를 인코딩하는 바이러스 벡터 |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
BR112021019959A2 (pt) | 2019-04-17 | 2022-02-08 | Novo Nordisk As | Anticorpo biespecífico, e, formulação farmacêutica |
CN112175088B (zh) * | 2019-07-02 | 2023-03-28 | 江苏晟斯生物制药有限公司 | 改进的fix融合蛋白、缀合物及其应用 |
WO2021043127A1 (zh) * | 2019-09-02 | 2021-03-11 | 甘李药业股份有限公司 | 嵌合蛋白 |
EP4038182A1 (en) | 2019-09-30 | 2022-08-10 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
CN113005176A (zh) * | 2019-12-20 | 2021-06-22 | 深圳市帝迈生物技术有限公司 | 稳定剂、凝血酶原时间检测试剂及其制备方法、试剂盒 |
US20230035308A1 (en) * | 2021-07-02 | 2023-02-02 | Aetio Biotherapy, Inc. | Activatable monomeric cytokine-single chain (sc) fc fusion proteins and uses thereof |
WO2023133469A2 (en) * | 2022-01-07 | 2023-07-13 | Codexis, Inc. | Recombinant factor viii variants |
Family Cites Families (201)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US659684A (en) | 1899-10-14 | 1900-10-16 | John A W Lundborg | Dental rubber-dam holder. |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
US4849407A (en) | 1986-08-13 | 1989-07-18 | Zymogenetics, Inc. | Biologically active mosaic proteins |
US5157021A (en) | 1985-03-15 | 1992-10-20 | Novo Nordisk A/S | Insulin derivatives and pharmaceutical preparations containing these derivatives |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
JPH0788399B2 (ja) | 1985-04-12 | 1995-09-27 | ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド | 新規プロコアギュラント蛋白質 |
US4745055A (en) | 1985-05-07 | 1988-05-17 | California Biotechnology Inc. | Fused protein for enzyme immunoassay system |
KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
JP2525022B2 (ja) | 1986-01-03 | 1996-08-14 | ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド | ▲VIII▼:c因子型タンパク質の改良生産方法 |
US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
IL78444A (en) | 1986-04-08 | 1992-05-25 | Yeda Res & Dev | Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody |
US5543502A (en) | 1986-06-24 | 1996-08-06 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
DE3751908T2 (de) | 1986-07-07 | 1997-02-06 | Centocor Inc | Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen |
NO873164L (no) | 1986-07-30 | 1988-02-01 | Teijin Ltd | Muse-humane kimaere antistoffer. |
IL84285A (en) | 1986-10-27 | 1993-03-15 | Int Genetic Engineering | Chimeric antibody with specificity to human tumor antigen |
GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
CA1339445C (en) | 1986-11-12 | 1997-09-09 | The General Hospital Corporation | Recombinant hybrid immunoglobulin molecules and method of use |
EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
IE69026B1 (en) | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
CA2057854C (en) | 1989-05-22 | 2000-01-11 | James D. Kelly | Pdgf .alpha.-receptor |
US5061786A (en) | 1989-05-25 | 1991-10-29 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
US5935815A (en) | 1989-10-25 | 1999-08-10 | Katholieke Universiteit Leuven | Process for micro biological production of proteins |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
US5648273A (en) | 1989-12-27 | 1997-07-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Hepatic growth factor receptor is the MET proto-oncogene |
ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CA2040099A1 (en) | 1990-05-01 | 1991-11-02 | Mariano Barbacid | Tyrosine kinase negative trkb |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5453491A (en) | 1990-09-11 | 1995-09-26 | Kiyoshi Takatsu | Murine interleukin-5 receptor |
CA2096418C (en) | 1990-11-26 | 2001-11-20 | Philip J. Barr | Expression of pace in host cells and methods of use thereof |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
EP0580751A1 (en) | 1991-04-19 | 1994-02-02 | Schering Corporation | Subunit of the human interleukin-3 receptor |
US5227158A (en) | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
US5346991A (en) | 1991-06-13 | 1994-09-13 | Genentech, Inc. | Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders |
US5348856A (en) | 1991-07-08 | 1994-09-20 | E. R. Squibb & Sons, Inc. | DNA encoding TRKC protein |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
EP0626012B1 (en) | 1992-02-11 | 2003-07-09 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
JP2559093Y2 (ja) | 1992-05-08 | 1998-01-14 | ワイケイケイ株式会社 | 面ファスナー |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
DE69332859T2 (de) | 1992-11-13 | 2003-12-18 | Idec Pharmaceuticals Corp., San Diego | Konsensus-kozak-sequenzen zur säugetier-exprimierung |
WO1994028017A1 (en) | 1993-06-01 | 1994-12-08 | The Scripps Research Institute | Human mutant tissue factor compositions useful as tissue factor antagonists |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
CN1162184C (zh) * | 1994-07-11 | 2004-08-18 | 德克萨斯州立大学董事会 | 用于脉管系统特异性凝血的组合物及其应用 |
GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US5840529A (en) | 1995-08-02 | 1998-11-24 | Clinical Research Institute Of Montreal | Mammalian pro-hormone convertase |
EP1382679A3 (en) | 1995-09-08 | 2004-11-10 | Genentech, Inc. | Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
JP2000515735A (ja) | 1996-07-03 | 2000-11-28 | ジェネンテック インコーポレーテッド | 肝細胞成長因子レセプターアゴニスト |
CA2203745A1 (en) | 1996-07-26 | 1998-01-26 | Robert Day | Pro-protein converting enzyme |
AU3968897A (en) | 1996-08-02 | 1998-02-25 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
US6159462A (en) | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
US5994104A (en) * | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
DK0951551T4 (da) | 1996-12-23 | 2012-09-10 | Immunex Corp | Ligand for NF-kappa B-receptoraktivator, ligand er medlem af TNF-superfamilien |
US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
PT981637E (pt) | 1997-03-14 | 2005-09-30 | Biogen Idec Inc | Metodo para integrar genes em sitios especificos em celulas de mamifero atraves de recombinacao homologa e vectores para a realizacao do mesmo |
WO1998056915A2 (en) | 1997-06-12 | 1998-12-17 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
ES2226335T3 (es) | 1998-01-23 | 2005-03-16 | Immunex Corporation | Receooctires de uk.18. |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
US6281331B1 (en) | 1998-03-23 | 2001-08-28 | Trimeris, Inc. | Methods and compositions for peptide synthesis |
PT1068241E (pt) | 1998-04-02 | 2007-11-19 | Genentech Inc | Variantes de anticorpos e respectivos fragmentos |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US6355782B1 (en) | 1998-07-09 | 2002-03-12 | Baylor College Of Medicine | Hypohidrotic ectodermal dyplasia genes and proteins |
EP1105475A1 (en) | 1998-07-15 | 2001-06-13 | Genentech, Inc. | Tissue factor protein variants with increased affinity for coagulation factor fvii/fviia |
US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
EP1141015B1 (en) | 1999-01-06 | 2009-07-15 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variants |
DE60016560T2 (de) | 1999-01-06 | 2005-12-15 | Genentech, Inc., South San Francisco | Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i) |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
CA2359067C (en) | 1999-01-15 | 2017-03-14 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
US6602977B1 (en) | 1999-04-19 | 2003-08-05 | Biovitrum Ab | Receptor structures |
SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
JP2003504315A (ja) * | 1999-07-01 | 2003-02-04 | エール ユニバーシティ | 血管新生標的免疫複合体 |
CA2377731A1 (en) * | 1999-07-02 | 2001-01-11 | Genentech, Inc. | Fusion peptides comprising a peptide ligand domain and a multimerization domain |
US6469136B1 (en) | 1999-07-07 | 2002-10-22 | Trimeris, Inc. | Methods and composition for peptide synthesis |
AU2001249389A1 (en) * | 2000-03-22 | 2001-10-03 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
WO2002002781A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
WO2002020565A2 (en) | 2000-09-08 | 2002-03-14 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
WO2002055110A2 (en) | 2000-10-25 | 2002-07-18 | Genzyme Corp | Methods for treating blood coagulation disorders |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
CA2436092A1 (en) | 2001-01-29 | 2002-08-08 | Idec Pharmaceutical Corporation | Modified antibodies and methods of use |
US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
US7235638B2 (en) * | 2001-03-22 | 2007-06-26 | Novo Nordisk Healthcare A/G | Coagulation factor VII derivatives |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
US20030082630A1 (en) | 2001-04-26 | 2003-05-01 | Maxygen, Inc. | Combinatorial libraries of monomer domains |
ES2288900T3 (es) | 2001-10-05 | 2008-02-01 | Affimed Therapeutics Ag | Anticuerpo de origen humano para inhibir la agregacion de trombocitos. |
FR2831170B1 (fr) | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
EP2990417A1 (en) | 2001-12-21 | 2016-03-02 | Human Genome Sciences, Inc. | Albumin insulin fusion protein |
US20040102440A1 (en) | 2002-07-01 | 2004-05-27 | Wong Erik Ho Fong | Method of promoting smoking cessation |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
CA2478011C (en) | 2002-03-01 | 2013-05-21 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
CA2479212A1 (en) | 2002-03-15 | 2003-09-25 | Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
AU2003241599A1 (en) * | 2002-05-22 | 2003-12-12 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of hemophilia a |
AU2003262650B2 (en) | 2002-08-14 | 2009-10-29 | Macrogenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
EP2364996B1 (en) | 2002-09-27 | 2016-11-09 | Xencor Inc. | Optimized FC variants and methods for their generation |
CA2502904C (en) | 2002-10-15 | 2013-05-28 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
GB2395337B (en) | 2002-11-14 | 2005-12-28 | Gary Michael Wilson | Warning Unit |
EP1587540B1 (en) | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
EP3002012A1 (en) * | 2003-05-06 | 2016-04-06 | Biogen Hemophilia Inc. | Clotting factor-fc chimeric proteins to treat hemophilia |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
CN1802167A (zh) * | 2003-06-12 | 2006-07-12 | 伊莱利利公司 | 融合蛋白质 |
MXPA06000487A (es) | 2003-07-25 | 2006-04-05 | Basf Ag | Dispersiones acuosas de polimerizados hidrosolubles de monomeros anionicos etilenicamente insaturados, metodo para la produccion y uso de los mismos. |
US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
TR201809892T4 (tr) | 2003-11-05 | 2018-07-23 | Roche Glycart Ag | Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller. |
AU2004290070A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
US20080193441A1 (en) * | 2003-11-18 | 2008-08-14 | Iconic Therapeutics, Inc. | Homogeneous Preparations of Chimeric Protein |
US20050249723A1 (en) | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
UA86605C2 (ru) | 2004-01-12 | 2009-05-12 | Аплайд Молекьюлер Иволюшн, Инк. | Антитело, которое содержит вариант исходного человеческого fс-участка |
WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
CA2564251C (en) | 2004-05-21 | 2018-04-10 | The Uab Research Foundation | Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof |
WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
BRPI0510674A (pt) | 2004-07-15 | 2007-12-26 | Xencor Inc | variantes fc otimizadas |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
JP2008520207A (ja) | 2004-11-16 | 2008-06-19 | アヴィディア リサーチ インスティテュート | タンパク質骨格およびその使用 |
EP3479844B1 (en) * | 2005-04-15 | 2023-11-22 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
US7427787B2 (en) | 2005-07-08 | 2008-09-23 | Texas Instruments Incorporated | Guardringed SCR ESD protection |
US7666622B2 (en) * | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
EP1820508A1 (en) | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
EA015992B1 (ru) | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
SI2004683T1 (sl) | 2006-03-24 | 2016-09-30 | Biogen Hemophilia Inc. | Pc5 kot encim za obdelavo propeptida faktorja ix |
CA2655248C (en) * | 2006-06-14 | 2016-02-09 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
US7939632B2 (en) * | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
US7833260B2 (en) | 2006-07-20 | 2010-11-16 | Orbusneich Medical, Inc. | Bioabsorbable polymeric medical device |
GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
EP1952822A1 (en) | 2007-01-26 | 2008-08-06 | Novo Nordisk A/S | Factor VII polypeptides with increased affinity to platelets |
WO2008131242A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
JP5398703B2 (ja) | 2007-05-14 | 2014-01-29 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 一本鎖FC(ScFc)領域、それを含む結合ポリペプチド、およびそれに関連する方法 |
AU2008314697B2 (en) | 2007-10-22 | 2013-08-29 | Merck Serono S.A. | Single IFN-beta fused to a mutated lgG Fc fragment |
TWI538916B (zh) * | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
KR20110022604A (ko) * | 2008-05-16 | 2011-03-07 | 바이엘 헬스케어 엘엘씨 | 표적화 응고 인자 및 그의 사용 방법 |
US8800831B2 (en) | 2009-08-19 | 2014-08-12 | Larry A. Gray | Multi-purpose rack and method thereof |
US20120093840A1 (en) * | 2009-04-06 | 2012-04-19 | Novo Nordisk A/S | Targeted delivery of factor viii proteins to platelets |
WO2010151736A1 (en) * | 2009-06-25 | 2010-12-29 | The University Of North Carolina At Chapel Hill | Chimeric factor vii molecules |
WO2011023785A1 (en) | 2009-08-27 | 2011-03-03 | Novo Nordisk A/S | Targeting tissue factor to activated platelets |
JP5903048B2 (ja) | 2009-12-06 | 2016-04-13 | バイオジェン ヘモフィリア インコーポレイテッド | 第VIII−Fc因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
US9014425B2 (en) | 2010-04-21 | 2015-04-21 | Optosecurity Inc. | Method and system for use in performing security screening |
KR20190104442A (ko) | 2010-07-09 | 2019-09-09 | 바이오버라티브 테라퓨틱스 인크. | 인자 ix 폴리펩티드 및 이들의 사용 방법 |
TW201217527A (en) | 2010-07-09 | 2012-05-01 | Biogen Idec Hemophilia Inc | Processable single chain molecules and polypeptides made using same |
US20130337537A1 (en) | 2011-03-02 | 2013-12-19 | Novo Nordisk A/S | Coagulation factor-targeting to tlt-1 on activated platelets |
-
2011
- 2011-07-11 TW TW100124536A patent/TW201217527A/zh unknown
- 2011-07-11 TW TW100124535A patent/TW201217526A/zh unknown
- 2011-07-11 ES ES11738539T patent/ES2739503T3/es active Active
- 2011-07-11 PL PL11738539T patent/PL2591006T3/pl unknown
- 2011-07-11 CA CA2804280A patent/CA2804280A1/en not_active Abandoned
- 2011-07-11 SI SI201131758T patent/SI2591006T1/sl unknown
- 2011-07-11 KR KR1020137003461A patent/KR20140002601A/ko not_active Application Discontinuation
- 2011-07-11 JP JP2013518877A patent/JP2013534427A/ja active Pending
- 2011-07-11 EA EA201291482A patent/EA201291482A1/ru unknown
- 2011-07-11 SG SG2012096608A patent/SG186875A1/en unknown
- 2011-07-11 NZ NZ605400A patent/NZ605400A/en not_active IP Right Cessation
- 2011-07-11 CN CN2011800424499A patent/CN103180439A/zh active Pending
- 2011-07-11 LT LTEP11738539.3T patent/LT2591006T/lt unknown
- 2011-07-11 AU AU2011274423A patent/AU2011274423B2/en active Active
- 2011-07-11 EP EP11738538.5A patent/EP2591099B1/en active Active
- 2011-07-11 DK DK11738538.5T patent/DK2591099T3/da active
- 2011-07-11 WO PCT/US2011/043599 patent/WO2012006635A1/en active Application Filing
- 2011-07-11 HU HUE11738539 patent/HUE044419T2/hu unknown
- 2011-07-11 SG SG10201505217WA patent/SG10201505217WA/en unknown
- 2011-07-11 US US13/809,289 patent/US20130216513A1/en not_active Abandoned
- 2011-07-11 DK DK11738539.3T patent/DK2591006T3/da active
- 2011-07-11 EP EP11738539.3A patent/EP2591006B1/en active Active
- 2011-07-11 MX MX2013000301A patent/MX2013000301A/es unknown
- 2011-07-11 PT PT11738539T patent/PT2591006T/pt unknown
- 2011-07-11 WO PCT/US2011/043597 patent/WO2012006633A1/en active Application Filing
- 2011-07-11 EP EP19165598.4A patent/EP3560962A1/en active Pending
- 2011-07-11 US US13/809,287 patent/US9856468B2/en active Active
-
2016
- 2016-07-27 US US15/221,420 patent/US10968442B2/en active Active
-
2017
- 2017-11-21 US US15/820,172 patent/US10927362B2/en active Active
-
2019
- 2019-07-18 HR HRP20191305TT patent/HRP20191305T1/hr unknown
- 2019-07-24 CY CY20191100782T patent/CY1122044T1/el unknown
-
2021
- 2021-01-19 US US17/152,470 patent/US20210292729A1/en active Pending
- 2021-04-05 US US17/222,636 patent/US20210355473A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191305T1 (hr) | Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste | |
JP2013534427A5 (hr) | ||
IL261432B1 (en) | Induced binding proteins and methods of use | |
JP2010534061A5 (hr) | ||
MX2012013233A (es) | Grupos que apuntan a receptor 2 de complemento (cr2) mejorados. | |
AR060583A1 (es) | Anticuerpo de c- kit humanizado | |
RU2014143639A (ru) | Регулируемые протеазой антитела | |
BRPI0516572A (pt) | métodos e composições para melhorar a produção de proteìnas recombinantes | |
WO2012045082A3 (en) | Engineered nucleic acids and methods of use thereof | |
EP3372617A3 (en) | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same | |
BR112015004696A2 (pt) | polipeptídeos quiméricos tendo especificidade de ligação alvejada | |
IN2012DN03368A (hr) | ||
ATE534737T1 (de) | Gezielte abgabe von sirna | |
MX360741B (es) | Constructos de polipéptidos y sus usos. | |
WO2012112696A8 (en) | Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells | |
WO2007064727A3 (en) | Penetrabodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases | |
RS52790B (en) | MONOCLONAL ANTIBODIES AGAINST CLAUDINE-18 FOR THE CANCER TREATMENT | |
ZA200800517B (en) | Transplastomic plants expressing lumen-targeted protein | |
PE20140867A1 (es) | Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso | |
MY159013A (en) | Recombinant protein production in avian ebx® cells | |
NZ593450A (en) | Vaccines based on targeting antigen to dcir expressed on antigen-presenting cells | |
SG157346A1 (en) | Improved purification of collagenases from clostridium histolyticum liquid culture | |
MX2009004464A (es) | Conjugados biomoleculares divididos, dirigidos para el tratamiento de enfermedades, malignidades y desordenes, y metodos para su produccion. | |
WO2007122511A3 (en) | Antibody-rnase-conjugate | |
CA3097742A1 (en) | Methods and compositions for genome editing |